Virtual conference

Opthea Announces Presentation at HC Wainwright’s 2nd Annual Virtual Ophthalmology Conference | Your money

MELBOURNE, Australia, Aug. 16, 2022 (GLOBE NEWSWIRE) — Opthea Limited (ASX: OPT; NASDAQ: OPT), a clinical-stage biopharmaceutical company developing novel therapies to treat widespread and progressive retinal diseases, announced that the Chief General, Dr. Megan Baldwin will present at HC Wainwright’s 2nd Annual Virtual Ophthalmology Conference, to be held virtually on August 17, 2022.

The presentation will be available at 7:00 a.m. ET (9:00 p.m. AET) and will be available for viewing for 90 days on the Investors page of Opthea’s website at

About Opthea Limited

Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of widespread and progressive retinal diseases, including wet age-related macular degeneration (wet AMD). and diabetic macular edema (DME). Opthea’s lead product candidate, OPT-302, is in pivotal Phase 3 clinical trials and is being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the aim of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting VEGF-A alone.

Risks inherent in investing in biotechnology companies

There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and effectiveness of a drug before it is marketed and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and granted patents will provide adequate protection to enable product development, obtaining necessary approvals from drug regulatory authorities and the difficulties caused by rapid advances in technology. Companies like Opthea are dependent on the success of their research and development projects and their ability to attract funding to support these activities. Investments in research and development projects cannot be evaluated on the same basis as commercial and manufacturing enterprises. Therefore, investing in drug development companies should be considered highly speculative. Opthea strongly recommends seeking professional investment advice before making such investments.

Cleared for broadcast on ASX by Megan Baldwin, CEO and Managing Director

Business and Media Inquiries:

Media: Silvana Guerci-Lena NorthStream Global Partners Tel. : +1 973-509-4671 [email protected]

Join our email database to receive program updates: Tel: +61 (0) 3 9826 0399 Email: [email protected] Web:

Copyright 2022 GlobeNewswire, Inc.